Skip to main content
SpringerLink
Log in

EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues

  • Guidelines
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001;42:432–45

    PubMed  CAS  Google Scholar 

  2. Langen KJ, Pauleit D, Coenen HH. 3-[123I]Iodo-α-methyl-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 2002;29:631

    Google Scholar 

  3. Laverman P, Boerman OC, Corstens FH, Oyen WJ. Fluorinated amino acids for tumour imaging with positron emission tomography. Eur J Nucl Med Mol Imaging 2002;29:681–690

    Article  PubMed  CAS  Google Scholar 

  4. Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M, et al. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 2004;10:7163–7170

    Article  PubMed  CAS  Google Scholar 

  5. Pauleit D, Floeth F, Herzog H, Hamacher K, Tellmann L, Müller HW, et al. Whole-body distribution and dosimetry of O-(2-[18F]fluoroethy)-L-tyrosine. Eur J Nucl Med Mol Imaging 2003;30:519–524

    Article  PubMed  CAS  Google Scholar 

  6. Pirotte B, Goldman S, Massager N, David P, Wikler D, Vandesteene A, et al. Comparison of18F-FDG and11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med 2004;45:1293–1298

    PubMed  CAS  Google Scholar 

  7. Riemann B, Papke K, Hoess N, Kuwert T, Weckesser M, Matheja P, et al. Noninvasive grading of untreated gliomas: a comparative study of MR imaging and 3-(iodine 123)-L-alpha-methyltyrosine SPECT. Radiology 2002;225:567–574

    PubMed  Google Scholar 

  8. Kracht LW, Friese M, Herholz K, Schroeder R, Bauer B, Jacobs A, et al. Methyl-[11C]- l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 2003;30:868–873

    Article  PubMed  CAS  Google Scholar 

  9. De Witte O, Goldberg I, Wikler D, Rorive S, Damhaut P, Monclus M, et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 2001;95:746–750

    Article  PubMed  Google Scholar 

  10. Levivier M, Massager N, Wikler D, Lorenzoni J, Ruiz S, Devriendt D, et al. Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors: clinical experience and proposed classification. J Nucl Med 2004;45:1146–1154

    PubMed  Google Scholar 

  11. Lahoutte T, Caveliers V, Franken PR, Bossuyt A, Mertens J, Everaert H. Increased tumor uptake of 3-123I-iodo-L-alpha-methyltyrosine after preloading with amino acids: an in vivo animal imaging study. J Nucl Med 2002;43:1201–1206

    PubMed  CAS  Google Scholar 

  12. Deloar HM, Fujiwara T, Nakamura T, Itoh M, Imai D, Miyake M, et al. Estimation of internal absorbed dose of L-[methyl-11C]methionine using whole-body positron emission tomography. Eur J Nucl Med 1998;25:629–633

    Article  PubMed  CAS  Google Scholar 

  13. Schmidt D, Langen KJ, Herzog H, Wirths J, Holschbach M, Kiwit JC, et al. Whole-body kinetics and dosimetry of L-3-123I-iodo-alpha-methyltyrosine. Eur J Nucl Med 1997;24:1162–1166

    PubMed  CAS  Google Scholar 

  14. Kuwert T, Morgenroth C, Woesler B, Matheja P, Palkovic S, Vollet B, et al. Uptake of iodine-123-alpha-methyl tyrosine by gliomas and non-neoplastic brain lesions. Eur J Nucl Med 1996;23:1345–1353

    Article  PubMed  CAS  Google Scholar 

  15. Kuwert T, Woesler B, Morgenroth C, Lerch H, Schafers M, Palkovic S, et al. Diagnosis of recurrent glioma with SPECT and iodine-123-alpha-methyl tyrosine. J Nucl Med 1998;39:23–27

    PubMed  CAS  Google Scholar 

  16. Weber WA, Dick S, Reidl G, Dzewas B, Busch R, Feldmann HJ, et al. Correlation between postoperative 3-[123I]iodo-L-alpha-methyltyrosine uptake and survival in patients with gliomas. J Nucl Med 2001;42:1144–1150

    PubMed  CAS  Google Scholar 

  17. Van Laere K, Ceyssens S, Van Calenbergh F, de Groot T, Menten J, Flamen P, et al. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging 2005;32:39–51

    Article  PubMed  CAS  Google Scholar 

  18. Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Muller HW, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 2005;128:678–687

    Article  PubMed  Google Scholar 

  19. Cook GJ, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med 1999;26:1363–1378

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The members of the ENC acknowledge the assistance provided by the following persons (in alphabetical order) in reading the guidelines and providing constructive comments based on their expertise: R.G. Blasberg, USA, E. Bombardieri, Italy, K. Ericson, Sweden, S. Goldman, Belgium, and K. Herholz, T. Kuwert, K.J. Langen and W. Weber, Germany.

Author information

Authors and Affiliations

  1. Nuclear Medicine Division, Mont-Godinne Medical Center, University Catholique de Louvain, Louvain, Belgium

    T. Vander Borght

  2. Department of Neurology, Medical University of Vienna, Vienna, Austria

    S. Asenbaum

  3. Department of Nuclear Medicine, Johannes Gutenberg University, Mainz, Germany

    P. Bartenstein

  4. Department of Clinical Neuroscience, Section of Psychiatry, Karolinska Institutet, Stockholm, Sweden

    C. Halldin

  5. Department of Nuclear Medicine, Gazi University, Ankara, Turkey

    Ö. Kapucu

  6. Division of Nuclear Medicine, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium

    K. Van Laere

  7. Biostructure and Bioimaging Institute, National Research Council, Napoli, Italy

    A. Varrone

  8. Department of Nuclear Medicine, Ludwig-Maximilians University, Marchioninistrasse 15, 81377, Munich, Germany

    K. Tatsch

Authors
  1. T. Vander Borght
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Asenbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Bartenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Halldin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ö. Kapucu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K. Van Laere
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Varrone
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K. Tatsch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Tatsch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vander Borght, T., Asenbaum, S., Bartenstein, P. et al. EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging 33, 1374–1380 (2006). https://doi.org/10.1007/s00259-006-0206-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-006-0206-3

Keywords

Search

Navigation